Drug-vitamin D interactions: A systematic review of the literature

Nutrition in Clinical Practice

Volumn 28, Issue 2, 2013, Pages 194-208

  Robien, Kim ^a   Oppeneer, Sarah J ^b   Kelly, Julia A ^b   Hamilton Reeves, Jill M ^c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

drug interactions; vitamin D

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BLOCKING AGENT; CALCITRIOL; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A4; DIGESTIVE TRACT AGENT; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PROTON PUMP INHIBITOR; THIAZIDE DIURETIC AGENT; VITAMIN D;

BONE MINERALIZATION; CASE CONTROL STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EXCRETION; DRUG METABOLISM; HEALTH CARE PERSONNEL; HUMAN; HYPERPARATHYROIDISM; KIDNEY FUNCTION; PERSONNEL; REVIEW; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; DRUG INTERACTIONS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; PHARMACEUTICAL PREPARATIONS; VITAMIN D; VITAMINS;

EID: 84875253113     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533612467824     Document Type: Review

References (174)

1. Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem Mol Biol. 2007 ; 103 (3-5). 558-562
2. Boucher BJ. Vitamin D insufficiency and diabetes risks. Curr Drug Targets. 2011 ; 12 (1). 61-87
3. Vitamin D and Cancer. Lyon, France: World Health Organization, IARC ; 2008 :
4. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. Curr Opin Pharmacol. 2010 ; 10 (4). 482-496
5. Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010 ; 106 (6). 798-805
6. Nutrition Business Journal. 2011 ; 16: 137-139
7. Moshfegh A, Goldman J, Ahuja J, Rhodes D, LaComb R What We Eat in America, NHANES 2005-2006: Usual Nutrient Intake From Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D, Calcium, Phosphorus and Magnesium. Beltsville, MD: US Department of Agriculture, Agricultural Research Service ; 2008 :
8. Office of Dietary Supplements, National Institutes of Health. Dietary supplement fact sheet: vitamin D. http://ods.od.nih.gov/factsheets/VitaminD- HealthProfessional#h9. Accessed November 17, 2011.
9. Henry HL Vitamin D. 25 -hydroxyvitamin D 1alpha-hydroxylase. In: FeldmanDPikeJWGloriueuxFH, eds. Vitamin D. Vol 1. 2nd ed.Boston: Academic Press; 2005:69-83. Feldman D Pike JW Gloriueux FH, ed. Boston: Academic Press ; 69-83.
10. Norman AW, Mizwicki MT, Norman DP. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov. 2004 ; 3 (1). 27-41
11. Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003 ; 1619 (3). 243-253
12. Chatterjee B, Echchgadda I, Song CS. Vitamin D receptor regulation of the steroid/bile acid sulfotransferase SULT2A1. Methods Enzymol. 2005 ; 400: 165-191
13. Fan J, Liu S, Du Y, Morrison J, Shipman R, Pang KS. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25- dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. J Pharmacol Exp Ther. 2009 ; 330 (2). 389-402
14. Dietary Reference Intakes for Vitamin D and Calcium. Washington, DC: Institute of Medicine ; 2011 :
15. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 ; 84 (1). 18-28
16. Vieth R, Bischoff-Ferrari H, Boucher BJ, et al. The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr. 2007 ; 85 (3). 649-650
17. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005 ; 135 (2). 317-322
18. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000 ; 72 (3). 690-693
19. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 ; 67 (2). 373-378
20. Dawson-Hughes B, Harris SS, Dallal GE. Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr. 1997 ; 65 (1). 67-71
21. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005 ; 16 (7). 713-716
22. Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab. 2004 ; 5 (6). 483-505
23. Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008 ; 9 (4). 310-322
24. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 1987 ; 80 (4). 1029-1036
25. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest. 1992 ; 90 (5). 1871-1878
26. Thummel KE, Brimer C, Yasuda K, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001 ; 60 (6). 1399-1406
27. Lindh JD, Andersson ML, Eliasson E, Bjorkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos. 2011 ; 39 (5). 933-937
28. Evidence Analysis Manual: Steps in the ADA Evidence Analysis Process. Chicago, IL: American Dietetic Association ; 2008 :
29. Hoogwerf BJ, Hibbard DM, Hunninghake DB. Effects of long-term cholestyramine administration on vitamin D and parathormone levels in middle-aged men with hypercholesterolemia. J Lab Clin Med. 1992 ; 119 (4). 407-411
30. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr. 1996 ; 129 (1). 42-49
31. Ismail F, Corder CN, Epstein S, Barbi G, Thomas S. Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites. Clin Ther. 1990 ; 12 (5). 427-430
32. Tsang RC, Roginsky MS, Mellies MJ, Glueck CJ. Plasma 25-hydroxy-vitamin D in familial hypercholesterolemic children receiving colestipol resin. Pediatr Res. 1978 ; 12 (10). 980-982
33. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics. 1980 ; 65 (2). 243-250
34. Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metab Clin Exp. 1994 ; 43 (3). 293-298
35. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997 ; 21: S12
36. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord. 2001 ; 25 (8). 1154-1160
37. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997 ; 21: S24 - S30
38. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 ; 22 (7). 814-822
39. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001 ; 292 (5519). 1160-1164
40. Dobs AS, Levine MA, Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism. 1991 ; 40 (5). 524-528
41. Montagnani M, Lore F, Di Cairano G, et al. Effects of pravastatin treatment on vitamin D metabolites. Clin Ther. 1994 ; 16 (5). 824-829
42. Vaughan CJ, Gotto AM. Update on statins: 2003. Circulation. 2004 ; 110 (7). 886-892
43. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002 ; 41 (5). 343-370
44. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid- lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006 ; 80 (6). 565-581
45. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther. 2009 ; 85 (2). 198-203
46. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007 ; 99 (7). 903-905
47. Perez-Castrillon JL, Abad L, Vega G, et al. Effect of atorvastatin on bone mineral density in patients with acute coronary syndrome. Eur Rev Med Pharmacol Sci. 2008 ; 12 (2). 83-88
48. Aloia JF, Li-Ng M, Pollack S. Statins and vitamin D. Am J Cardiol. 2007 ; 100 (8). 1329
49. Gauvain S. Calciferol in the treatment of tuberculous glands. Tubercle. 1948 ; 29 (11). 259-264
50. Chocano Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. Nutr. Rev. 2009 ; 67 (5). 289-293
51. Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol. 2008 ; 37 (1). 113-119
52. Zhou S, Chan E, Lim LY, et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 ; 5 (5). 415-442
53. Brodie MJ, Boobis AR, Dollery CT, et al. Rifampicin and vitamin D metabolism. Clin Pharmacol Ther. 1980 ; 27 (6). 810-814
54. Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Park BK. Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther. 1981 ; 30 (3). 363-367
55. Brodie MJ, Boobis AR, Hillyard CJ, et al. Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther. 1982 ; 32 (4). 525-530
56. Davies PD, Brown RC, Church HA, Woodhead JS. The effect of anti-tuberculosis chemotherapy on vitamin D and calcium metabolism. Tubercle. 1987 ; 68 (4). 261-266
57. Williams SE, Wardman AG, Taylor GA, Peacock M, Cooke NJ. Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism. Tubercle. 1985 ; 66 (1). 49-54
58. Martinez ME, Gonzalez J, Sanchez-Cabezudo MJ, Pena JM, Vazquez JJ. Remission of hypercalciuria in patients with tuberculosis after treatment. Calcif Tissue Int. 1996 ; 59 (1). 17-20
59. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology. 2008 ; 47: 920-923
60. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 ; 24 (2). 87-92
61. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 ; 115 (1). 177-186
62. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 ; 69 (1). 56-65
63. Morijiri Y, Sato T. Factors causing rickets in institutionalised handicapped children on anticonvulsant therapy. Arch Dis Child. 1981 ; 56 (6). 446-449
64. Krause KH, Berlit P, Bonjour JP, Schmidt-Gayk H, Schellenberg B, Gillen J. Vitamin status in patients on chronic anticonvulsant therapy. Int J Vitam Nutr Res. 1982 ; 52 (4). 375-385
65. Gough H, Bissesar A, Goggin T, et al. Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy. Ir J Med Sci. 1986 ; 155 (6). 181-189
66. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med. 1986 ; 59 (230). 569-577
67. Nettekoven S, Strohle A, Trunz B, et al. Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy. Eur J Pediatr. 2008 ; 167 (12). 1369-1377
68. Hahn TJ, Hendin BA, Scharp CR, Haddad JG. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med. 1972 ; 287 (18). 900-904
69. Bouillon R, Reynaert J, Claes JH, Lissens W, De Moor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab. 1975 ; 41 (06). 1130-1135
70. Jubiz W, Haussler MR, McCain TA, Tolman KG. Plasma 1,25-dihydroxyvitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab. 1977 ; 44 (4). 617-621
71. Pylypchuk G, Oreopoulos DG, Wilson DR, et al. Calcium metabolism in adult outpatients with epilepsy receiving long-term anticonvulsant therapy. Can Med Assoc J. 1978 ; 118 (6). 635-638
72. Weisman Y, Andriola M, Reiter E, Gruskin A, Root A. Serum concentrations of 25-hydroxyvitamin D in Florida children: effect of anticonvulsant drugs. South Med J. 1979 ; 72 (4). 400 408-401
73. Christensen CK, Lund B, Lund BJ, Sorensen OH, Nielsen HE, Mosekilde L. Reduced 2,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D in epileptic patients receiving chronic combined anticonvulsant therapy. Metab Bone Dis Relat Res. 1981 ; 3 (1). 17-22
74. Hoikka V, Savolainen K, Alhava EM, Sivenius J, Karjalainen P, Repo A. Osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Acta Neurol Scand. 1981 ; 64 (2). 122-131
75. Hoikka V, Savolainen K, Karjalainen P, Alhava EM, Sivenius J. Treatment of osteomalacia in institutionalized epileptic patients on long-term anticonvulsant therapy. Ann Clin Res. 1982 ; 14 (2). 72-75
76. Keck E, Gollnick B, Reinhardt D, Karch D, Peerenboom H, Kruskemper HL. Calcium metabolism and vitamin D metabolite levels in children receiving anticonvulsant drugs. Eur J Pediatr. 1982 ; 139 (1). 52-55
77. Lamberg-Allardt C, Wilska M, Saraste KL, Gronlund T. Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment. Ann Nutr Metab. 1990 ; 34 (4). 216-220
78. Valimaki MJ, Tiihonen M, Laitinen K, et al. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J Bone Miner Res. 1994 ; 9 (5). 631-637
79. Baer MT, Kozlowski BW, Blyler EM, Trahms CM, Taylor ML, Hogan MP. Vitamin D, calcium, and bone status in children with developmental delay in relation to anticonvulsant use and ambulatory status. Am J Clin Nutr. 1997 ; 65 (4). 1042-1051
80. Henderson RC. Vitamin D levels in noninstitutionalized children with cerebral palsy. J Child Neurol. 1997 ; 12 (7). 443-447
81. Telci A, Cakatay U, Kurt BB, et al. Changes in bone turnover and deoxypyridinoline levels in epileptic patients. Clin Chem Lab Med. 2000 ; 38 (1). 47-50
82. Filardi S, Guerreiro CA, Magna LA, Marques Neto JF. Bone mineral density, vitamin D and anticonvulsant therapy. Arq Neuropsiquiatr. 2000 ; 58 (3A). 616-620
83. Mintzer S, Boppana P, Toguri J, DeSantis A. Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia. 2006 ; 47 (3). 510-515
84. Stamp TC, Round JM, Rowe DJ, Haddad JG. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J. 1972 ; 4 (5831). 9-12
85. Weisman Y, Fattal A, Eisenberg Z, Harel S, Spirer Z, Harell A. Decreased serum 24,25-dehydroxy vitamin D concentrations in children receiving chronic anticonvulsant therapy. Br Med J. 1979 ; 2 (6189). 521-523
86. Tjellesen L, Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand. 1982 ; 66 (3). 335-341
87. Zerwekh JE, Homan R, Tindall R, Pak CY. Decreased serum 24,25-dihydroxyvitamin D concentration during long-term anticonvulsant therapy in adult epileptics. Ann Neurol. 1982 ; 12 (2). 184-186
88. Davie MW, Emberson CE, Lawson DE, et al. Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med. 1983 ; 52 (205). 79-91
89. Hoikka V, Alhava EM, Karjalainen P, et al. Carbamazepine and bone mineral metabolism. Acta Neurol Scand. 1984 ; 70 (2). 77-80
90. Rajantie J, Lamberg-Allardt C, Wilska M. Does carbamazepine treatment lead to a need of extra vitamin D in some mentally retarded children?. Acta Paediatr Scand. 1984 ; 73 (3). 325-328
91. Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab. 1984 ; 58 (6). 1003-1009
92. Williams C, Netzloff M, Folkerts L, Vargas A, Garnica A, Frias J. Vitamin D metabolism and anticonvulsant therapy: effect of sunshine on incidence of osteomalacia. South Med J. 1984 ; 77 (7). 834 842-836
93. Nishiyama S, Kuwahara T, Matsuda I. Decreased bone density in severely handicapped children and adults, with reference to the influence of limited mobility and anticonvulsant medication. Eur J Pediatr. 1986 ; 144 (5). 457-463
94. Fogelman I, Gray JM, Gardner MD, et al. Do anticonvulsant drugs commonly induce osteomalacia?. Scott Med J. 1982 ; 27 (2). 136-142
95. Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001 ; 42 (9). 1141-1147
96. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002 ; 58 (9). 1348-1353
97. Marcus JC, Pettifor JM. Folate and mineral metabolism in poorly nourished epileptic children. Arch Neurol. 1980 ; 37 (12). 772-774
98. Maeda K, Ikeda H. High 1,25-dihydroxyvitamin D and low 25-hydroxyvitamin D concentrations in plasma in patients receiving antiepileptic drugs. Jpn J Psychiatry Neurol. 1986 ; 40 (1). 57-60
99. Winnacker JL, Yeager H, Saunders JA, Russell B, Anast CS. Rickets in children receiving anticonvulsant drugs: biochemical and hormonal markers. Am J Dis Child. 1977 ; 131 (3). 286-290
100. Markestad T, Ulstein M, Strandjord RE, Aksnes L, Aarskog D. Anticonvulsant drug therapy in human pregnancy: effects on serum concentrations of vitamin D metabolites in maternal and cord blood. Am J Obstet Gynecol. 1984 ; 150 (3). 254-258
101. Ala-Houhala M, Korpela R, Koivikko M, Koskinen T, Koskinen M, Koivula T. Long-term anticonvulsant therapy and vitamin D metabolism in ambulatory pubertal children. Neuropediatrics. 1986 ; 17 (4). 212-216
102. Riancho JA, del Arco C, Arteaga R, Herranz JL, Albajar M, Macias JG. Influence of solar irradiation on vitamin D levels in children on anticonvulsant drugs. Acta Neurol Scand. 1989 ; 79 (4). 296-299
103. Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin D status in children: prospective monitoring study. J Child Neurol. 2006 ; 21 (3). 205-209
104. Bramswig S, Zittermann A, Berthold HK. Carbamazepine does not alter biochemical parameters of bone turnover in healthy male adults. Calcif Tissue Int. 2003 ; 73 (4). 356-360
105. Bergqvist AG, Schall JI, Stallings VA. Vitamin D status in children with intractable epilepsy, and impact of the ketogenic diet. Epilepsia. 2007 ; 48 (1). 66-71
106. Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008 ; 70 (18). 1586-1593
107. Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav. 2007 ; 10 (2). 291-295
108. Cansu A, Yesilkaya E, Serdaroglu A, et al. Evaluation of bone turnover in epileptic children using oxcarbazepine. Pediatr Neurol. 2008 ; 39 (4). 266-271
109. Hoikka V, Savolainen K, Alhava EM, Sivenius J, Karjalainen P, Parvianinen M. Anticonvulsant osteomalacia in epileptic outpatients. Ann Clin Res. 1982 ; 14 (3). 129-132
110. Rickers H, Deding A, Christiansen C, Rodbro P, Naestoft J. Corticosteroid-induced osteopenia and vitamin D metabolism: effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol (Oxf). 1982 ; 16 (4). 409-415
111. Zerwekh JE, Emkey RD, Harris ED. Low-dose prednisone therapy in rheumatoid arthritis: effect on vitamin D metabolism. Arthritis Rheum. 1984 ; 27 (9). 1050-1052
112. Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981 ; 52 (1). 111-115
113. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991 ; 72 (2). 382-386
114. Lems WF, Jacobs JW, Van Rijn HJ, Bijlsma JW. Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Clin Rheumatol. 1995 ; 14 (4). 420-424
115. Halton JM, Atkinson SA, Fraher L, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res. 1996 ; 11 (11). 1774-1783
116. Hahn TJ, Halstead LR, Haddad JG. Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med. 1977 ; 90 (2). 399-404
117. Klein RG, Arnaud SB, Gallagher JC, Deluca HF, Riggs BL. Intestinal calcium absorption in exogenous hypercortisonism: role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest. 1977 ; 60 (1). 253-259
118. Lund B, Storm TL, Melsen F, et al. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment. Clin Rheumatol. 1985 ; 4 (2). 143-149
119. Bikle DD, Halloran B, Fong L, Steinbach L, Shellito J. Elevated 1,25-dihydroxyvitamin D levels in patients with chronic obstructive pulmonary disease treated with prednisone. J Clin Endocrinol Metab. 1993 ; 76 (2). 456-461
120. Wetzsteon RJ, Shults J, Zemel BS, et al. Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome. J Bone Miner Res. 2009 ; 24 (3). 503-513
121. Wolthers OD, Riis BJ, Pedersen S. Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide. Pediatr Pulmonol. 1993 ; 16 (6). 341-346
122. Bijlsma JW, Duursma SA, Huber-Bruning O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann Rheum Dis. 1986 ; 45 (9). 757-760
123. Slovik DM, Neer RM, Ohman JL, et al. Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients. Clin Endocrinol. 1980 ; 12 (3). 243-248
124. Als OS, Riis B, Christiansen C. Serum concentration of vitamin D metabolites in rheumatoid arthritis. Clin Rheumatol. 1987 ; 6 (2). 238-243
125. von Scheven E, Gordon CM, Wypij D, Wertz M, Gallagher KT, Bachrach L. Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study. J Pediatr Endocrinol Metab. 2006 ; 19 (6). 821-830
126. Sentongo TA, Semaeo EJ, Stettler N, Piccoli DA, Stallings VA, Zemel BS. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr. 2002 ; 76 (5). 1077-1081
127. Cohran VC, Griffiths M, Heubi JE. Bone mineral density in children exposed to chronic glucocorticoid therapy. Clin Pediatr. 2008 ; 47 (5). 469-475
128. Santiago RA, Silva CA, Caparbo VF, Sallum AM, Pereira RM. Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use. Scand J Rheumatol. 2008 ; 37 (1). 40-47
129. Princen HM, Meijer P, Wolthers BG, Vonk RJ, Kuipers F. Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J. 1991 ; 275 (pt 2). 501-505
130. Winegar DA, Salisbury JA, Sundseth SS, Hawke RL. Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res. 1996 ; 37 (1). 179-191
131. Souidi M, Parquet M, Ferezou J, Lutton C. Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. Life Sci. 1999 ; 64 (17). 1585-1593
132. Gueguen Y, Ferrari L, Souidi M, et al. Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol. 2007 ; 100 (6). 392-397
133. Grenet O, Bobadilla M, Chibout SD, Steiner S. Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol. 2000 ; 59 (3). 267-272
134. Reichel H, Grussinger A, Knehans A, Kuhn K, Schmidt-Gayk H, Ritz E. Long-term therapy with cyclosporin A does not influence serum concentrations of vitamin D metabolites in patients with multiple sclerosis. Clin Investig. 1992 ; 70 (7). 595-599
135. de Sevaux RG, Hoitsma AJ, van Hoof HJ, Corstens FJ, Wetzels JF. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract. 2003 ; 93 (1). C21 - C28
136. Saha HH, Salmela KT, Ahonen PJ, et al. Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. Scand J Urol Nephrol. 1994 ; 28 (1). 21-27
137. Shaw AJ, Hayes ME, Davies M, et al. Cyclosporin A and vitamin D metabolism: studies in patients with psoriasis and in rats. Clin Sci. 1994 ; 86 (5). 627-632
138. Edwards BD, Davies M, Mawer EB, Chalmers RJ, Testa HJ, Ballardie FW. Interrelationship between serum concentrations of 1,25-dihydroxyvitamin D, parathyroid hormone and renal haemodynamics after low dose cyclosporin. Miner Electrolyte Metab. 1994 ; 20 (5). 250-254
139. Falkiewicz K, Kaminska D, Nahaczewska W, et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. Transplant Proc. 2006 ; 38 (1). 119-122
140. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007 ; 22 (5). 328-335
141. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006 ; 11 (7). 742-752
142. Kailajarvi ME, Salminen EK, Paija OM, Virtanent AM, Leino AE, Irjala KA. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res. 2004 ; 24 (2C). 1271-1274
143. Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr J. 1993 ; 40 (6). 737-742
144. Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis. 2009 ; 24 (2). 219-224
145. Flexner C Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11 th ed.New York: McGraw-Hill; 2006. Brunton LL Lazo JS Parker KL, ed. New York: McGraw-Hill ; 2006 :
146. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007 ; 29 (6). 687-710
147. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003 ; 17 (4). 513-520
148. Ramayo E, Gonzalez-Moreno MP, Macias J, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005 ; 21 (11). 915-921
149. Curtis JR, Smith B, Weaver M, et al. Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Res Hum Retroviruses. 2006 ; 22 (2). 125-131
150. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006 ; 25 (4). 537-539
151. Bengoa JM, Bolt MJ, Rosenberg IH. Hepatic vitamin D 25-hydroxylase inhibition by cimetidine and isoniazid. J Lab Clin Med. 1984 ; 104 (4). 546-552
152. Wyatt CL, Jensen LS, Rowland GN. Effect of cimetidine on eggshell quality and plasma 25-hydroxycholecalciferol in laying hens. Poult Sci. 1990 ; 69 (11). 1892-1899
153. Odes HS, Fraser GM, Krugliak P, Lamprecht SA, Shany S. Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion. 1990 ; 46 (2). 61-64
154. Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. J Clin Gastroenterol. 1983 ; 5: 81-90
155. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007 ; 85 (1). 6-18
156. Parfitt AM. Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. N Engl J Med. 1969 ; 281 (2). 55-59
157. Lichtwitz A, Parlier R, de S, Hioco D, Miravet L. The hypocalciuric effect of diuretic sulfonamides [in French]. Sem Med Prof Med Soc. 1961 ; 37: 2350-2362
158. Torsti P, Lamberg BA. The effect of a two-day treatment with chlorothiazide on the urinary excretion of calcium, phosphate and sodium in hyper- and hypocalcemia. Acta Med Scand. 1964 ; 175: 181-191
159. Higgins BA, Nassim JR, Collins J, Hilb A. The effect of bendrofluazide on urine calcium excretion. Clin Sci. 1964 ; 27: 457-462
160. Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriatr Soc. 1984 ; 32 (5). 405-407
161. Crowe M, Wollner L, Griffiths RA. Hypercalcaemia following vitamin D and thiazide therapy in the elderly. Practitioner. 1984 ; 228 (1389). 312-313
162. Riis B, Christiansen C. Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause. Metab Clin Exp. 1985 ; 34 (5). 421-424
163. Lemann J, Gray RW, Maierhofer WJ, Cheung HS. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int. 1985 ; 28 (6). 951-958
164. Kokot F, Pietrek J, Srokowska S, et al. 25-Hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981 ; 16 (4). 188-192
165. Perry HM, Jensen J, Kaiser FE, Horowitz M, Perry HM, Morley JE. The effects of thiazide diuretics on calcium metabolism in the aged. J Am Geriatr Soc. 1993 ; 41 (8). 818-822
166. Huang H, Wang H, Sinz M, et al. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene. 2007 ; 26 (2). 258-268
167. Marechal JD, Yu J, Brown S, et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab Dispos. 2006 ; 34 (4). 534-538
168. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983 ; 71 (5). 1495-1499
169. Hollis BW, Horst RL. The assessment of circulating 25(OH)D and 1,25(OH)2D: where we are and where we are going. J Steroid Biochem Mol Biol. 2007 ; 103 (3-5). 473-476
170. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004 ; 89 (7). 3152-3157
171. Carter GD, Carter CR, Gunter E, et al. Measurement of vitamin D metabolites: an international perspective on methodology and clinical interpretation. J Steroid Biochem Mol Biol. 2004 ; 89-90 (1-5). 467-471
172. Tai SS, Bedner M, Phinney KW. Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem. 2010 ; 82 (5). 1942-1948
173. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 ; 34 (1-2). 83-448
174. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005 ; 44 (3). 279-304